Higia., Inc. d/b/a Eden appears in FDA records as the applicant for Eden PACS, cleared substantially equivalent on 21 October 2026 under K261788. The submission was received 29 May 2026, reviewed in the Radiology panel, and processed as an abbreviated 510(k) with a summary statement. The device is classified as a System, Image Processing, Radiological, a Class II category under 21 CFR 892.2050 and product code LLZ. The same applicant name and device identity appear across the FDA record and third-party indexes of that record. [1][2][6][8]

The K261788 filing and its scope

K261788 lists Eden PACS as the device and Higia., Inc. d/b/a Eden as the applicant, with a decision of substantially equivalent dated 21 October 2026. The record shows an abbreviated clearance type, no third-party review, and a summary statement. The advisory committee is Radiology, matching the device’s classification as a radiological image-processing system. The filing address is in Wilmington, Delaware; that address is a correspondence detail in the FDA record and is not presented here as a corporate headquarters. [1][6][8]

Independent indexes of the same filing repeat the device name, applicant, product code LLZ, regulation 21 CFR 892.2050, Class II designation, and the 21 October 2026 decision date. One index also lists a correspondent, Hardian Ltd. d/b/a Hardian Health, in London, alongside a 510(k) summary reference for Higia, Inc. The correspondent’s role in the submission is not described in the available text. [6][8]

Published platform description

Eden’s own technology page describes a Diagnostic OS intended to replace a fragmented stack of PACS, RIS, viewer, and reporting tools with one cloud-native system, covering steps from scheduling and image capture through diagnosis, reporting, delivery, and measurement. The company’s homepage describes infrastructure plus frontier AI that converts diagnostic data into clinical answers, organized around a Diagnostic OS, a dataset, and frontier AI. These are the manufacturer’s descriptions of its product architecture, not independently verified performance claims. [4][7]

Legal entity and brand naming

Eden’s legal page defines “Eden / Eden Group” as Higia, Inc. and any subsidiaries, affiliates, or related entities that participate in processing personal data. That definition ties the Eden brand to the Higia, Inc. legal name used in the FDA filing. The legal page also sets out terms of use and a global privacy notice governing the company’s platforms and services. No parent company, ownership structure, or headquarters location is established by the available records. [3]

Portfolio context

The linked FDA record set for this company contains one 510(k) entry, K261788, with a decision count of one substantially equivalent. That count reflects the records retrieved as of 20 November 2026 and is not a measure of total company portfolio, sales, or safety performance. A broader FDA query covering decisions from 15 October to 11 November 2026 returned 192 results, a separate collection that does not describe this applicant. [1][5]